Journal of Pharmacoeconomics and Pharmaceutical Management (Jul 2017)
Cost-effectiveness analysis of cinacalcet versus vitamin D analogs in secondary hyperparathyroidism in end-stage renal disease patients on dialysis (Protocol)
Abstract
Background: Chronic kidney disease (CKD) is an irreversible and progressive deterioration of renal function. The terminate stage of CKD is known as end-stage renal disease (ESRD) at which the patient needs a renal replacement therapy such as dialysis. Secondary hyperparathyroidism (SHPT) - excessive production of parathyroid hormone - is a common complication of impaired renal function. Patients with ESRD are likely at high risk for varying degrees of SHPT. Guidelines recommend pharmacotherapy as the main treatment of SHPT. Cinacalcet is a new medicine for treating patients with SHPT. The aim of this paper was to describe the background, rationale, objectives, design, and methodology of cost-effectiveness analysis of cinacalcet for SHPT in ESRD patients. Methods: We will perform a systematic review of the approved databases and literature to collect randomized control trials on SHPT. The definitions, data sources, methods of data gathering, and data generating will be explained in this paper. One-way sensitivity analysis will be used for estimating the robustness of our results. Conclusion: This study helps to obtain information concerning the cost-effectiveness of using cinacalcet in the treatment regimen of SHPT patients. The result will assist policy makers and physicians to support the most cost-effective pharmaceutical therapy for SHPT patients. This would increase allocative efficiency of the health-care delivery system in Iran.